265 related articles for article (PubMed ID: 21047542)
1. Enhanced endothelial delivery and biochemical effects of α-galactosidase by ICAM-1-targeted nanocarriers for Fabry disease.
Hsu J; Serrano D; Bhowmick T; Kumar K; Shen Y; Kuo YC; Garnacho C; Muro S
J Control Release; 2011 Feb; 149(3):323-31. PubMed ID: 21047542
[TBL] [Abstract][Full Text] [Related]
2. Enhanced delivery of α-glucosidase for Pompe disease by ICAM-1-targeted nanocarriers: comparative performance of a strategy for three distinct lysosomal storage disorders.
Hsu J; Northrup L; Bhowmick T; Muro S
Nanomedicine; 2012 Jul; 8(5):731-9. PubMed ID: 21906578
[TBL] [Abstract][Full Text] [Related]
3. Comparative binding, endocytosis, and biodistribution of antibodies and antibody-coated carriers for targeted delivery of lysosomal enzymes to ICAM-1 versus transferrin receptor.
Papademetriou J; Garnacho C; Serrano D; Bhowmick T; Schuchman EH; Muro S
J Inherit Metab Dis; 2013 May; 36(3):467-77. PubMed ID: 22968581
[TBL] [Abstract][Full Text] [Related]
4. Optimizing endothelial targeting by modulating the antibody density and particle concentration of anti-ICAM coated carriers.
Calderon AJ; Bhowmick T; Leferovich J; Burman B; Pichette B; Muzykantov V; Eckmann DM; Muro S
J Control Release; 2011 Feb; 150(1):37-44. PubMed ID: 21047540
[TBL] [Abstract][Full Text] [Related]
5. Effect of flow on endothelial endocytosis of nanocarriers targeted to ICAM-1.
Bhowmick T; Berk E; Cui X; Muzykantov VR; Muro S
J Control Release; 2012 Feb; 157(3):485-92. PubMed ID: 21951807
[TBL] [Abstract][Full Text] [Related]
6. Lysosomal delivery of therapeutic enzymes in cell models of Fabry disease.
Marchesan D; Cox TM; Deegan PB
J Inherit Metab Dis; 2012 Nov; 35(6):1107-17. PubMed ID: 22450713
[TBL] [Abstract][Full Text] [Related]
7. Control of endothelial targeting and intracellular delivery of therapeutic enzymes by modulating the size and shape of ICAM-1-targeted carriers.
Muro S; Garnacho C; Champion JA; Leferovich J; Gajewski C; Schuchman EH; Mitragotri S; Muzykantov VR
Mol Ther; 2008 Aug; 16(8):1450-8. PubMed ID: 18560419
[TBL] [Abstract][Full Text] [Related]
8. Enhancing biodistribution of therapeutic enzymes in vivo by modulating surface coating and concentration of ICAM-1-targeted nanocarriers.
Hsu J; Bhowmick T; Burks SR; Kao JP; Muro S
J Biomed Nanotechnol; 2014 Feb; 10(2):345-54. PubMed ID: 24738342
[TBL] [Abstract][Full Text] [Related]
9. A fibrinogen-derived peptide provides intercellular adhesion molecule-1-specific targeting and intraendothelial transport of polymer nanocarriers in human cell cultures and mice.
Garnacho C; Serrano D; Muro S
J Pharmacol Exp Ther; 2012 Mar; 340(3):638-47. PubMed ID: 22160267
[TBL] [Abstract][Full Text] [Related]
10. Transport of nanocarriers across gastrointestinal epithelial cells by a new transcellular route induced by targeting ICAM-1.
Ghaffarian R; Bhowmick T; Muro S
J Control Release; 2012 Oct; 163(1):25-33. PubMed ID: 22698938
[TBL] [Abstract][Full Text] [Related]
11. Reduced glucosylceramide in the mouse model of Fabry disease: correction by successful enzyme replacement therapy.
Quinta R; Rodrigues D; Assunção M; Macedo MF; Azevedo O; Cunha D; Oliveira P; Sá Miranda MC
Gene; 2014 Feb; 536(1):97-104. PubMed ID: 24334116
[TBL] [Abstract][Full Text] [Related]
12. Characterization of Fabry mice treated with recombinant adeno-associated virus 2/8-mediated gene transfer.
Choi JO; Lee MH; Park HY; Jung SC
J Biomed Sci; 2010 Apr; 17(1):26. PubMed ID: 20398385
[TBL] [Abstract][Full Text] [Related]
13. Lysosomal enzyme delivery by ICAM-1-targeted nanocarriers bypassing glycosylation- and clathrin-dependent endocytosis.
Muro S; Schuchman EH; Muzykantov VR
Mol Ther; 2006 Jan; 13(1):135-41. PubMed ID: 16153895
[TBL] [Abstract][Full Text] [Related]
14. Pathogenesis and Molecular Mechanisms of Anderson-Fabry Disease and Possible New Molecular Addressed Therapeutic Strategies.
Tuttolomondo A; Simonetta I; Riolo R; Todaro F; Di Chiara T; Miceli S; Pinto A
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576250
[TBL] [Abstract][Full Text] [Related]
15. Combination-targeting to multiple endothelial cell adhesion molecules modulates binding, endocytosis, and in vivo biodistribution of drug nanocarriers and their therapeutic cargoes.
Papademetriou I; Tsinas Z; Hsu J; Muro S
J Control Release; 2014 Aug; 188():87-98. PubMed ID: 24933603
[TBL] [Abstract][Full Text] [Related]
16. Endothelial targeting of high-affinity multivalent polymer nanocarriers directed to intercellular adhesion molecule 1.
Muro S; Dziubla T; Qiu W; Leferovich J; Cui X; Berk E; Muzykantov VR
J Pharmacol Exp Ther; 2006 Jun; 317(3):1161-9. PubMed ID: 16505161
[TBL] [Abstract][Full Text] [Related]
17.
Kytidou K; Beekwilder J; Artola M; van Meel E; Wilbers RHP; Moolenaar GF; Goosen N; Ferraz MJ; Katzy R; Voskamp P; Florea BI; Hokke CH; Overkleeft HS; Schots A; Bosch D; Pannu N; Aerts JMFG
J Biol Chem; 2018 Jun; 293(26):10042-10058. PubMed ID: 29674318
[TBL] [Abstract][Full Text] [Related]
18. Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice.
Jung SC; Han IP; Limaye A; Xu R; Gelderman MP; Zerfas P; Tirumalai K; Murray GJ; During MJ; Brady RO; Qasba P
Proc Natl Acad Sci U S A; 2001 Feb; 98(5):2676-81. PubMed ID: 11226298
[TBL] [Abstract][Full Text] [Related]
19. Delivery of acid sphingomyelinase in normal and niemann-pick disease mice using intercellular adhesion molecule-1-targeted polymer nanocarriers.
Garnacho C; Dhami R; Simone E; Dziubla T; Leferovich J; Schuchman EH; Muzykantov V; Muro S
J Pharmacol Exp Ther; 2008 May; 325(2):400-8. PubMed ID: 18287213
[TBL] [Abstract][Full Text] [Related]
20. ICAM-1 recycling in endothelial cells: a novel pathway for sustained intracellular delivery and prolonged effects of drugs.
Muro S; Gajewski C; Koval M; Muzykantov VR
Blood; 2005 Jan; 105(2):650-8. PubMed ID: 15367437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]